nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—RET—thyroid cancer	0.346	1	CbGaD
Vandetanib—MKNK1—Sorafenib—thyroid cancer	0.0594	0.128	CbGbCtD
Vandetanib—FLT4—Sorafenib—thyroid cancer	0.0497	0.107	CbGbCtD
Vandetanib—FLT3—Sorafenib—thyroid cancer	0.0429	0.0925	CbGbCtD
Vandetanib—KDR—Sorafenib—thyroid cancer	0.0429	0.0925	CbGbCtD
Vandetanib—RET—Sorafenib—thyroid cancer	0.0429	0.0925	CbGbCtD
Vandetanib—EPHB6—Sorafenib—thyroid cancer	0.038	0.0818	CbGbCtD
Vandetanib—EPHA6—Sorafenib—thyroid cancer	0.038	0.0818	CbGbCtD
Vandetanib—STK10—Sorafenib—thyroid cancer	0.0341	0.0735	CbGbCtD
Vandetanib—PDGFRB—Sorafenib—thyroid cancer	0.031	0.0669	CbGbCtD
Vandetanib—MAP2K5—Sorafenib—thyroid cancer	0.031	0.0669	CbGbCtD
Vandetanib—MAP3K19—Sorafenib—thyroid cancer	0.0285	0.0615	CbGbCtD
Vandetanib—ABCC1—Epirubicin—thyroid cancer	0.00961	0.0207	CbGbCtD
Vandetanib—ABCG2—Sorafenib—thyroid cancer	0.00563	0.0121	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—thyroid cancer	0.00511	0.011	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—thyroid cancer	0.00342	0.00736	CbGbCtD
Vandetanib—RET—parathyroid gland—thyroid cancer	0.00268	0.0521	CbGeAlD
Vandetanib—CYP3A4—Sorafenib—thyroid cancer	0.00122	0.00262	CbGbCtD
Vandetanib—PTK6—saliva-secreting gland—thyroid cancer	0.0012	0.0233	CbGeAlD
Vandetanib—PTK6—trachea—thyroid cancer	0.000927	0.018	CbGeAlD
Vandetanib—RET—neck—thyroid cancer	0.000813	0.0158	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—thyroid cancer	0.000738	0.00159	CbGbCtD
Vandetanib—RIPK2—saliva-secreting gland—thyroid cancer	0.000714	0.0139	CbGeAlD
Vandetanib—IRAK4—saliva-secreting gland—thyroid cancer	0.000697	0.0135	CbGeAlD
Vandetanib—ERBB3—saliva-secreting gland—thyroid cancer	0.000683	0.0133	CbGeAlD
Vandetanib—LTK—head—thyroid cancer	0.000679	0.0132	CbGeAlD
Vandetanib—EPHA8—head—thyroid cancer	0.000651	0.0126	CbGeAlD
Vandetanib—SLK—saliva-secreting gland—thyroid cancer	0.000608	0.0118	CbGeAlD
Vandetanib—KDR—neck—thyroid cancer	0.000605	0.0117	CbGeAlD
Vandetanib—MAP4K5—saliva-secreting gland—thyroid cancer	0.000577	0.0112	CbGeAlD
Vandetanib—BMPR1B—thyroid gland—thyroid cancer	0.000556	0.0108	CbGeAlD
Vandetanib—EPHB6—saliva-secreting gland—thyroid cancer	0.000552	0.0107	CbGeAlD
Vandetanib—RIPK2—trachea—thyroid cancer	0.000551	0.0107	CbGeAlD
Vandetanib—VEGFA—trachea—thyroid cancer	0.000549	0.0107	CbGeAlD
Vandetanib—FMO1—trachea—thyroid cancer	0.000546	0.0106	CbGeAlD
Vandetanib—EPHA6—head—thyroid cancer	0.000543	0.0105	CbGeAlD
Vandetanib—IRAK4—trachea—thyroid cancer	0.000538	0.0104	CbGeAlD
Vandetanib—YES1—saliva-secreting gland—thyroid cancer	0.000533	0.0104	CbGeAlD
Vandetanib—ERBB3—trachea—thyroid cancer	0.000527	0.0102	CbGeAlD
Vandetanib—PDGFRB—neck—thyroid cancer	0.000524	0.0102	CbGeAlD
Vandetanib—TYRO3—head—thyroid cancer	0.000503	0.00977	CbGeAlD
Vandetanib—EPHA5—head—thyroid cancer	0.000503	0.00977	CbGeAlD
Vandetanib—LYN—head—thyroid cancer	0.000501	0.00972	CbGeAlD
Vandetanib—BMPR1B—head—thyroid cancer	0.000493	0.00957	CbGeAlD
Vandetanib—MAP3K19—head—thyroid cancer	0.000493	0.00957	CbGeAlD
Vandetanib—LCK—trachea—thyroid cancer	0.000489	0.00949	CbGeAlD
Vandetanib—AXL—trachea—thyroid cancer	0.000487	0.00945	CbGeAlD
Vandetanib—BLK—lymph node—thyroid cancer	0.000481	0.00933	CbGeAlD
Vandetanib—LTK—lymph node—thyroid cancer	0.000475	0.00922	CbGeAlD
Vandetanib—STK35—thyroid gland—thyroid cancer	0.000473	0.00917	CbGeAlD
Vandetanib—KDR—saliva-secreting gland—thyroid cancer	0.000472	0.00916	CbGeAlD
Vandetanib—MAP2K5—saliva-secreting gland—thyroid cancer	0.000472	0.00916	CbGeAlD
Vandetanib—SLK—trachea—thyroid cancer	0.000469	0.0091	CbGeAlD
Vandetanib—ABL2—thyroid gland—thyroid cancer	0.000461	0.00894	CbGeAlD
Vandetanib—FYN—trachea—thyroid cancer	0.000456	0.00885	CbGeAlD
Vandetanib—EGFR—thyroid gland—thyroid cancer	0.000449	0.00873	CbGeAlD
Vandetanib—MAP4K5—trachea—thyroid cancer	0.000445	0.00865	CbGeAlD
Vandetanib—FLT4—thyroid gland—thyroid cancer	0.000438	0.0085	CbGeAlD
Vandetanib—RIPK2—thyroid gland—thyroid cancer	0.000436	0.00846	CbGeAlD
Vandetanib—VEGFA—thyroid gland—thyroid cancer	0.000435	0.00844	CbGeAlD
Vandetanib—FMO1—thyroid gland—thyroid cancer	0.000432	0.00839	CbGeAlD
Vandetanib—EPHB6—trachea—thyroid cancer	0.000426	0.00826	CbGeAlD
Vandetanib—IRAK4—thyroid gland—thyroid cancer	0.000425	0.00826	CbGeAlD
Vandetanib—STK35—head—thyroid cancer	0.000419	0.00814	CbGeAlD
Vandetanib—ERBB3—thyroid gland—thyroid cancer	0.000417	0.0081	CbGeAlD
Vandetanib—YES1—trachea—thyroid cancer	0.000411	0.00798	CbGeAlD
Vandetanib—PDGFRB—saliva-secreting gland—thyroid cancer	0.000408	0.00793	CbGeAlD
Vandetanib—MKNK1—thyroid gland—thyroid cancer	0.000392	0.0076	CbGeAlD
Vandetanib—FLT4—head—thyroid cancer	0.000389	0.00754	CbGeAlD
Vandetanib—FGR—thyroid gland—thyroid cancer	0.000387	0.00751	CbGeAlD
Vandetanib—RET—thyroid gland—thyroid cancer	0.000387	0.00751	CbGeAlD
Vandetanib—LCK—thyroid gland—thyroid cancer	0.000387	0.00751	CbGeAlD
Vandetanib—RIPK2—head—thyroid cancer	0.000387	0.0075	CbGeAlD
Vandetanib—AXL—thyroid gland—thyroid cancer	0.000385	0.00748	CbGeAlD
Vandetanib—FMO1—head—thyroid cancer	0.000383	0.00744	CbGeAlD
Vandetanib—IRAK4—head—thyroid cancer	0.000377	0.00733	CbGeAlD
Vandetanib—PLK4—lymph node—thyroid cancer	0.000375	0.00728	CbGeAlD
Vandetanib—FMO3—thyroid gland—thyroid cancer	0.000374	0.00725	CbGeAlD
Vandetanib—SLK—thyroid gland—thyroid cancer	0.000371	0.0072	CbGeAlD
Vandetanib—ERBB3—head—thyroid cancer	0.00037	0.00718	CbGeAlD
Vandetanib—ABL1—saliva-secreting gland—thyroid cancer	0.000364	0.00707	CbGeAlD
Vandetanib—KDR—trachea—thyroid cancer	0.000364	0.00707	CbGeAlD
Vandetanib—MAP2K5—trachea—thyroid cancer	0.000364	0.00707	CbGeAlD
Vandetanib—FYN—thyroid gland—thyroid cancer	0.000361	0.007	CbGeAlD
Vandetanib—TEK—thyroid gland—thyroid cancer	0.000352	0.00684	CbGeAlD
Vandetanib—MAP4K5—thyroid gland—thyroid cancer	0.000352	0.00684	CbGeAlD
Vandetanib—MKNK1—head—thyroid cancer	0.000347	0.00674	CbGeAlD
Vandetanib—BMPR1B—lymph node—thyroid cancer	0.000345	0.0067	CbGeAlD
Vandetanib—RET—head—thyroid cancer	0.000343	0.00666	CbGeAlD
Vandetanib—FGR—head—thyroid cancer	0.000343	0.00666	CbGeAlD
Vandetanib—AXL—head—thyroid cancer	0.000342	0.00663	CbGeAlD
Vandetanib—EPHB6—thyroid gland—thyroid cancer	0.000337	0.00654	CbGeAlD
Vandetanib—FMO3—head—thyroid cancer	0.000331	0.00643	CbGeAlD
Vandetanib—YES1—thyroid gland—thyroid cancer	0.000325	0.00632	CbGeAlD
Vandetanib—STK10—thyroid gland—thyroid cancer	0.000322	0.00626	CbGeAlD
Vandetanib—FYN—head—thyroid cancer	0.00032	0.00621	CbGeAlD
Vandetanib—PDGFRB—trachea—thyroid cancer	0.000315	0.00612	CbGeAlD
Vandetanib—SRC—thyroid gland—thyroid cancer	0.000313	0.00608	CbGeAlD
Vandetanib—MAP4K5—head—thyroid cancer	0.000313	0.00607	CbGeAlD
Vandetanib—TEK—head—thyroid cancer	0.000313	0.00607	CbGeAlD
Vandetanib—FLT3—lymph node—thyroid cancer	0.0003	0.00582	CbGeAlD
Vandetanib—EPHB6—head—thyroid cancer	0.000299	0.0058	CbGeAlD
Vandetanib—STK35—lymph node—thyroid cancer	0.000294	0.0057	CbGeAlD
Vandetanib—YES1—head—thyroid cancer	0.000289	0.0056	CbGeAlD
Vandetanib—KDR—thyroid gland—thyroid cancer	0.000288	0.00559	CbGeAlD
Vandetanib—MAP2K5—thyroid gland—thyroid cancer	0.000288	0.00559	CbGeAlD
Vandetanib—ABL2—lymph node—thyroid cancer	0.000286	0.00555	CbGeAlD
Vandetanib—STK10—head—thyroid cancer	0.000286	0.00555	CbGeAlD
Vandetanib—ABL1—trachea—thyroid cancer	0.000281	0.00545	CbGeAlD
Vandetanib—EGFR—lymph node—thyroid cancer	0.000279	0.00542	CbGeAlD
Vandetanib—SRC—head—thyroid cancer	0.000278	0.00539	CbGeAlD
Vandetanib—FLT4—lymph node—thyroid cancer	0.000272	0.00528	CbGeAlD
Vandetanib—RIPK2—lymph node—thyroid cancer	0.000271	0.00525	CbGeAlD
Vandetanib—VEGFA—lymph node—thyroid cancer	0.00027	0.00524	CbGeAlD
Vandetanib—FMO1—lymph node—thyroid cancer	0.000268	0.00521	CbGeAlD
Vandetanib—IRAK4—lymph node—thyroid cancer	0.000264	0.00513	CbGeAlD
Vandetanib—ERBB3—lymph node—thyroid cancer	0.000259	0.00503	CbGeAlD
Vandetanib—MAP2K5—head—thyroid cancer	0.000255	0.00496	CbGeAlD
Vandetanib—KDR—head—thyroid cancer	0.000255	0.00496	CbGeAlD
Vandetanib—PDGFRB—thyroid gland—thyroid cancer	0.000249	0.00484	CbGeAlD
Vandetanib—MKNK1—lymph node—thyroid cancer	0.000243	0.00472	CbGeAlD
Vandetanib—RET—lymph node—thyroid cancer	0.00024	0.00466	CbGeAlD
Vandetanib—LCK—lymph node—thyroid cancer	0.00024	0.00466	CbGeAlD
Vandetanib—FGR—lymph node—thyroid cancer	0.00024	0.00466	CbGeAlD
Vandetanib—AXL—lymph node—thyroid cancer	0.000239	0.00465	CbGeAlD
Vandetanib—FMO3—lymph node—thyroid cancer	0.000232	0.0045	CbGeAlD
Vandetanib—SLK—lymph node—thyroid cancer	0.00023	0.00447	CbGeAlD
Vandetanib—ABCG2—saliva-secreting gland—thyroid cancer	0.00023	0.00446	CbGeAlD
Vandetanib—PLK4—Doxorubicin—Epirubicin—thyroid cancer	0.000229	0.115	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Epirubicin—thyroid cancer	0.000229	0.115	CbGdCrCtD
Vandetanib—FYN—lymph node—thyroid cancer	0.000224	0.00435	CbGeAlD
Vandetanib—ABL1—thyroid gland—thyroid cancer	0.000222	0.00431	CbGeAlD
Vandetanib—PDGFRB—head—thyroid cancer	0.000221	0.00429	CbGeAlD
Vandetanib—MAP4K5—lymph node—thyroid cancer	0.000219	0.00425	CbGeAlD
Vandetanib—TEK—lymph node—thyroid cancer	0.000219	0.00425	CbGeAlD
Vandetanib—ABCC1—trachea—thyroid cancer	0.000214	0.00415	CbGeAlD
Vandetanib—PLK4—Epirubicin—Doxorubicin—thyroid cancer	0.000212	0.106	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—thyroid cancer	0.000212	0.106	CbGdCrCtD
Vandetanib—EPHB6—lymph node—thyroid cancer	0.000209	0.00406	CbGeAlD
Vandetanib—YES1—lymph node—thyroid cancer	0.000202	0.00392	CbGeAlD
Vandetanib—STK10—lymph node—thyroid cancer	0.0002	0.00389	CbGeAlD
Vandetanib—ABL1—head—thyroid cancer	0.000197	0.00383	CbGeAlD
Vandetanib—Erythema multiforme—Sorafenib—thyroid cancer	0.000196	0.00397	CcSEcCtD
Vandetanib—Skin ulcer—Epirubicin—thyroid cancer	0.000196	0.00397	CcSEcCtD
Vandetanib—Laryngitis—Doxorubicin—thyroid cancer	0.000196	0.00397	CcSEcCtD
Vandetanib—SRC—lymph node—thyroid cancer	0.000194	0.00377	CbGeAlD
Vandetanib—ABL1—Doxorubicin—Epirubicin—thyroid cancer	0.000193	0.0966	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—thyroid cancer	0.000193	0.0966	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—thyroid cancer	0.000193	0.0966	CbGdCrCtD
Vandetanib—Cardiac disorder—Sorafenib—thyroid cancer	0.000192	0.0039	CcSEcCtD
Vandetanib—Haemoptysis—Doxorubicin—thyroid cancer	0.00019	0.00386	CcSEcCtD
Vandetanib—Ventricular arrhythmia—Doxorubicin—thyroid cancer	0.00019	0.00386	CcSEcCtD
Vandetanib—Angiopathy—Sorafenib—thyroid cancer	0.000188	0.00381	CcSEcCtD
Vandetanib—Mediastinal disorder—Sorafenib—thyroid cancer	0.000187	0.00378	CcSEcCtD
Vandetanib—Arrhythmia—Sorafenib—thyroid cancer	0.000185	0.00375	CcSEcCtD
Vandetanib—Alopecia—Sorafenib—thyroid cancer	0.000183	0.00371	CcSEcCtD
Vandetanib—Fungal infection—Doxorubicin—thyroid cancer	0.000183	0.0037	CcSEcCtD
Vandetanib—Mental disorder—Sorafenib—thyroid cancer	0.000181	0.00368	CcSEcCtD
Vandetanib—Skin ulcer—Doxorubicin—thyroid cancer	0.000181	0.00367	CcSEcCtD
Vandetanib—Malnutrition—Sorafenib—thyroid cancer	0.00018	0.00366	CcSEcCtD
Vandetanib—KDR—lymph node—thyroid cancer	0.000179	0.00347	CbGeAlD
Vandetanib—MAP2K5—lymph node—thyroid cancer	0.000179	0.00347	CbGeAlD
Vandetanib—ABL1—Epirubicin—Doxorubicin—thyroid cancer	0.000178	0.0894	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—thyroid cancer	0.000178	0.0894	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—thyroid cancer	0.000178	0.0894	CbGdCrCtD
Vandetanib—Dysgeusia—Sorafenib—thyroid cancer	0.000176	0.00358	CcSEcCtD
Vandetanib—Muscle spasms—Sorafenib—thyroid cancer	0.000173	0.00351	CcSEcCtD
Vandetanib—ABCC1—thyroid gland—thyroid cancer	0.000169	0.00328	CbGeAlD
Vandetanib—Cellulitis—Epirubicin—thyroid cancer	0.000168	0.0034	CcSEcCtD
Vandetanib—Hypocalcaemia—Epirubicin—thyroid cancer	0.000166	0.00338	CcSEcCtD
Vandetanib—Blood bilirubin increased—Epirubicin—thyroid cancer	0.000161	0.00327	CcSEcCtD
Vandetanib—Creatinine increased—Epirubicin—thyroid cancer	0.00016	0.00325	CcSEcCtD
Vandetanib—Loss of consciousness—Sorafenib—thyroid cancer	0.000158	0.00321	CcSEcCtD
Vandetanib—Cough—Sorafenib—thyroid cancer	0.000157	0.00319	CcSEcCtD
Vandetanib—Hypertension—Sorafenib—thyroid cancer	0.000156	0.00316	CcSEcCtD
Vandetanib—Cellulitis—Doxorubicin—thyroid cancer	0.000155	0.00314	CcSEcCtD
Vandetanib—PDGFRB—lymph node—thyroid cancer	0.000155	0.00301	CbGeAlD
Vandetanib—Hypocalcaemia—Doxorubicin—thyroid cancer	0.000154	0.00312	CcSEcCtD
Vandetanib—Arthralgia—Sorafenib—thyroid cancer	0.000153	0.00311	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000152	0.00309	CcSEcCtD
Vandetanib—Dry mouth—Sorafenib—thyroid cancer	0.00015	0.00304	CcSEcCtD
Vandetanib—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.000149	0.00302	CcSEcCtD
Vandetanib—Cystitis noninfective—Epirubicin—thyroid cancer	0.000149	0.00302	CcSEcCtD
Vandetanib—Creatinine increased—Doxorubicin—thyroid cancer	0.000148	0.003	CcSEcCtD
Vandetanib—Cystitis—Epirubicin—thyroid cancer	0.000147	0.00298	CcSEcCtD
Vandetanib—Colitis—Epirubicin—thyroid cancer	0.000146	0.00297	CcSEcCtD
Vandetanib—Infection—Sorafenib—thyroid cancer	0.000146	0.00296	CcSEcCtD
Vandetanib—ORM1—lymph node—thyroid cancer	0.000145	0.00282	CbGeAlD
Vandetanib—Nervous system disorder—Sorafenib—thyroid cancer	0.000144	0.00293	CcSEcCtD
Vandetanib—Thrombocytopenia—Sorafenib—thyroid cancer	0.000144	0.00292	CcSEcCtD
Vandetanib—Skin disorder—Sorafenib—thyroid cancer	0.000143	0.0029	CcSEcCtD
Vandetanib—Dry eye—Epirubicin—thyroid cancer	0.000141	0.00285	CcSEcCtD
Vandetanib—ABCG2—thyroid gland—thyroid cancer	0.00014	0.00272	CbGeAlD
Vandetanib—ABL1—lymph node—thyroid cancer	0.000138	0.00268	CbGeAlD
Vandetanib—Neoplasm—Epirubicin—thyroid cancer	0.000138	0.00279	CcSEcCtD
Vandetanib—Bladder pain—Epirubicin—thyroid cancer	0.000138	0.00279	CcSEcCtD
Vandetanib—Cystitis noninfective—Doxorubicin—thyroid cancer	0.000138	0.00279	CcSEcCtD
Vandetanib—Cystitis—Doxorubicin—thyroid cancer	0.000136	0.00276	CcSEcCtD
Vandetanib—Colitis—Doxorubicin—thyroid cancer	0.000135	0.00275	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000134	0.00272	CcSEcCtD
Vandetanib—Sepsis—Epirubicin—thyroid cancer	0.000132	0.00268	CcSEcCtD
Vandetanib—Dyspnoea—Sorafenib—thyroid cancer	0.000131	0.00266	CcSEcCtD
Vandetanib—Dry eye—Doxorubicin—thyroid cancer	0.00013	0.00264	CcSEcCtD
Vandetanib—Dyspepsia—Sorafenib—thyroid cancer	0.000129	0.00263	CcSEcCtD
Vandetanib—Decreased appetite—Sorafenib—thyroid cancer	0.000128	0.00259	CcSEcCtD
Vandetanib—Neoplasm—Doxorubicin—thyroid cancer	0.000127	0.00259	CcSEcCtD
Vandetanib—Bladder pain—Doxorubicin—thyroid cancer	0.000127	0.00259	CcSEcCtD
Vandetanib—ALB—lymph node—thyroid cancer	0.000127	0.00247	CbGeAlD
Vandetanib—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000127	0.00258	CcSEcCtD
Vandetanib—Fatigue—Sorafenib—thyroid cancer	0.000127	0.00257	CcSEcCtD
Vandetanib—Pain—Sorafenib—thyroid cancer	0.000126	0.00255	CcSEcCtD
Vandetanib—Constipation—Sorafenib—thyroid cancer	0.000126	0.00255	CcSEcCtD
Vandetanib—Sepsis—Doxorubicin—thyroid cancer	0.000122	0.00248	CcSEcCtD
Vandetanib—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00012	0.00244	CcSEcCtD
Vandetanib—Body temperature increased—Sorafenib—thyroid cancer	0.000116	0.00236	CcSEcCtD
Vandetanib—Abdominal pain—Sorafenib—thyroid cancer	0.000116	0.00236	CcSEcCtD
Vandetanib—Dermatitis bullous—Epirubicin—thyroid cancer	0.000116	0.00235	CcSEcCtD
Vandetanib—Cardiac failure—Epirubicin—thyroid cancer	0.000113	0.0023	CcSEcCtD
Vandetanib—Hypoglycaemia—Epirubicin—thyroid cancer	0.000113	0.0023	CcSEcCtD
Vandetanib—Lethargy—Epirubicin—thyroid cancer	0.000113	0.00229	CcSEcCtD
Vandetanib—Hyponatraemia—Epirubicin—thyroid cancer	0.000111	0.00225	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000111	0.00224	CcSEcCtD
Vandetanib—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000107	0.00217	CcSEcCtD
Vandetanib—Asthenia—Sorafenib—thyroid cancer	0.000106	0.00214	CcSEcCtD
Vandetanib—Cardiac arrest—Epirubicin—thyroid cancer	0.000105	0.00213	CcSEcCtD
Vandetanib—ABCC1—lymph node—thyroid cancer	0.000105	0.00204	CbGeAlD
Vandetanib—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000105	0.00213	CcSEcCtD
Vandetanib—Cardiac failure—Doxorubicin—thyroid cancer	0.000105	0.00213	CcSEcCtD
Vandetanib—Lethargy—Doxorubicin—thyroid cancer	0.000104	0.00212	CcSEcCtD
Vandetanib—Pruritus—Sorafenib—thyroid cancer	0.000104	0.00211	CcSEcCtD
Vandetanib—Blood creatinine increased—Epirubicin—thyroid cancer	0.000104	0.0021	CcSEcCtD
Vandetanib—Dehydration—Epirubicin—thyroid cancer	0.000103	0.00209	CcSEcCtD
Vandetanib—Hyponatraemia—Doxorubicin—thyroid cancer	0.000103	0.00208	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000102	0.00208	CcSEcCtD
Vandetanib—Dry skin—Epirubicin—thyroid cancer	0.000101	0.00206	CcSEcCtD
Vandetanib—Hypokalaemia—Epirubicin—thyroid cancer	0.000101	0.00204	CcSEcCtD
Vandetanib—Diarrhoea—Sorafenib—thyroid cancer	0.000101	0.00204	CcSEcCtD
Vandetanib—Nasopharyngitis—Epirubicin—thyroid cancer	9.89e-05	0.00201	CcSEcCtD
Vandetanib—Gastritis—Epirubicin—thyroid cancer	9.79e-05	0.00199	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	9.75e-05	0.00198	CcSEcCtD
Vandetanib—Cardiac arrest—Doxorubicin—thyroid cancer	9.73e-05	0.00197	CcSEcCtD
Vandetanib—Dizziness—Sorafenib—thyroid cancer	9.72e-05	0.00197	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—thyroid cancer	9.58e-05	0.00194	CcSEcCtD
Vandetanib—Influenza—Epirubicin—thyroid cancer	9.56e-05	0.00194	CcSEcCtD
Vandetanib—Dysphagia—Epirubicin—thyroid cancer	9.56e-05	0.00194	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—thyroid cancer	9.51e-05	0.00193	CcSEcCtD
Vandetanib—Dry skin—Doxorubicin—thyroid cancer	9.38e-05	0.0019	CcSEcCtD
Vandetanib—Pancreatitis—Epirubicin—thyroid cancer	9.37e-05	0.0019	CcSEcCtD
Vandetanib—Vomiting—Sorafenib—thyroid cancer	9.35e-05	0.0019	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—thyroid cancer	9.31e-05	0.00189	CcSEcCtD
Vandetanib—Rash—Sorafenib—thyroid cancer	9.27e-05	0.00188	CcSEcCtD
Vandetanib—Dermatitis—Sorafenib—thyroid cancer	9.26e-05	0.00188	CcSEcCtD
Vandetanib—Headache—Sorafenib—thyroid cancer	9.21e-05	0.00187	CcSEcCtD
Vandetanib—Bronchitis—Epirubicin—thyroid cancer	9.19e-05	0.00186	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—thyroid cancer	9.15e-05	0.00186	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—thyroid cancer	9.05e-05	0.00184	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	9.02e-05	0.00183	CcSEcCtD
Vandetanib—Neutropenia—Epirubicin—thyroid cancer	8.94e-05	0.00181	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—thyroid cancer	8.94e-05	0.00181	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Epirubicin—thyroid cancer	8.88e-05	0.0018	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—thyroid cancer	8.84e-05	0.00179	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—thyroid cancer	8.84e-05	0.00179	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—thyroid cancer	8.83e-05	0.00179	CcSEcCtD
Vandetanib—Nausea—Sorafenib—thyroid cancer	8.73e-05	0.00177	CcSEcCtD
Vandetanib—Photosensitivity reaction—Epirubicin—thyroid cancer	8.72e-05	0.00177	CcSEcCtD
Vandetanib—ABCG2—lymph node—thyroid cancer	8.7e-05	0.00169	CbGeAlD
Vandetanib—Pancreatitis—Doxorubicin—thyroid cancer	8.67e-05	0.00176	CcSEcCtD
Vandetanib—Weight decreased—Epirubicin—thyroid cancer	8.65e-05	0.00175	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—thyroid cancer	8.62e-05	0.00175	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—thyroid cancer	8.57e-05	0.00174	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—thyroid cancer	8.52e-05	0.00173	CcSEcCtD
Vandetanib—Infestation—Epirubicin—thyroid cancer	8.52e-05	0.00173	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—thyroid cancer	8.5e-05	0.00173	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	8.45e-05	0.00171	CcSEcCtD
Vandetanib—Renal failure—Epirubicin—thyroid cancer	8.38e-05	0.0017	CcSEcCtD
Vandetanib—Stomatitis—Epirubicin—thyroid cancer	8.31e-05	0.00169	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—thyroid cancer	8.28e-05	0.00168	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—thyroid cancer	8.28e-05	0.00168	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—thyroid cancer	8.27e-05	0.00168	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—thyroid cancer	8.27e-05	0.00168	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—thyroid cancer	8.22e-05	0.00167	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—thyroid cancer	8.17e-05	0.00166	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—thyroid cancer	8.12e-05	0.00165	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—thyroid cancer	8.07e-05	0.00164	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—thyroid cancer	8.06e-05	0.00164	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—thyroid cancer	8.04e-05	0.00163	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—thyroid cancer	8e-05	0.00162	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—thyroid cancer	7.99e-05	0.00162	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—thyroid cancer	7.98e-05	0.00162	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—thyroid cancer	7.93e-05	0.00161	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—thyroid cancer	7.88e-05	0.0016	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—thyroid cancer	7.88e-05	0.0016	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	7.82e-05	0.00159	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—thyroid cancer	7.79e-05	0.00158	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—thyroid cancer	7.75e-05	0.00157	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—thyroid cancer	7.69e-05	0.00156	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—thyroid cancer	7.68e-05	0.00156	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—thyroid cancer	7.66e-05	0.00155	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—thyroid cancer	7.66e-05	0.00155	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—thyroid cancer	7.65e-05	0.00155	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—thyroid cancer	7.55e-05	0.00153	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—thyroid cancer	7.52e-05	0.00153	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—thyroid cancer	7.5e-05	0.00152	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—thyroid cancer	7.46e-05	0.00151	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—thyroid cancer	7.44e-05	0.00151	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—thyroid cancer	7.4e-05	0.0015	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—thyroid cancer	7.37e-05	0.0015	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—thyroid cancer	7.23e-05	0.00147	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—thyroid cancer	7.21e-05	0.00146	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—thyroid cancer	7.15e-05	0.00145	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—thyroid cancer	7.11e-05	0.00144	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—thyroid cancer	7.1e-05	0.00144	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—thyroid cancer	7.08e-05	0.00144	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—thyroid cancer	6.99e-05	0.00142	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—thyroid cancer	6.94e-05	0.00141	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—thyroid cancer	6.94e-05	0.00141	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—thyroid cancer	6.89e-05	0.0014	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—thyroid cancer	6.83e-05	0.00139	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—thyroid cancer	6.82e-05	0.00138	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—thyroid cancer	6.76e-05	0.00137	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—thyroid cancer	6.7e-05	0.00136	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—thyroid cancer	6.69e-05	0.00136	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—thyroid cancer	6.66e-05	0.00135	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—thyroid cancer	6.61e-05	0.00134	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—thyroid cancer	6.57e-05	0.00133	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—thyroid cancer	6.52e-05	0.00132	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—thyroid cancer	6.42e-05	0.0013	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—thyroid cancer	6.4e-05	0.0013	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—thyroid cancer	6.38e-05	0.00129	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—thyroid cancer	6.32e-05	0.00128	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—thyroid cancer	6.28e-05	0.00127	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—thyroid cancer	6.25e-05	0.00127	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—thyroid cancer	6.2e-05	0.00126	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—thyroid cancer	6.16e-05	0.00125	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—thyroid cancer	6.03e-05	0.00122	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—thyroid cancer	5.92e-05	0.0012	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—thyroid cancer	5.85e-05	0.00119	CcSEcCtD
Vandetanib—Cough—Epirubicin—thyroid cancer	5.81e-05	0.00118	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—thyroid cancer	5.81e-05	0.00118	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—thyroid cancer	5.77e-05	0.00117	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—thyroid cancer	5.75e-05	0.00117	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—thyroid cancer	5.67e-05	0.00115	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—thyroid cancer	5.67e-05	0.00115	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—thyroid cancer	5.65e-05	0.00115	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	5.63e-05	0.00114	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—thyroid cancer	5.54e-05	0.00112	CcSEcCtD
Vandetanib—Oedema—Epirubicin—thyroid cancer	5.43e-05	0.0011	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—thyroid cancer	5.42e-05	0.0011	CcSEcCtD
Vandetanib—Infection—Epirubicin—thyroid cancer	5.4e-05	0.0011	CcSEcCtD
Vandetanib—Cough—Doxorubicin—thyroid cancer	5.38e-05	0.00109	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—thyroid cancer	5.34e-05	0.00108	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—thyroid cancer	5.33e-05	0.00108	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—thyroid cancer	5.32e-05	0.00108	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—thyroid cancer	5.32e-05	0.00108	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—thyroid cancer	5.28e-05	0.00107	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—thyroid cancer	5.25e-05	0.00106	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—thyroid cancer	5.25e-05	0.00106	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—thyroid cancer	5.23e-05	0.00106	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	5.21e-05	0.00106	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—thyroid cancer	5.13e-05	0.00104	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—thyroid cancer	5.03e-05	0.00102	CcSEcCtD
Vandetanib—Infection—Doxorubicin—thyroid cancer	5e-05	0.00101	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	4.95e-05	0.001	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—thyroid cancer	4.93e-05	0.001	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—thyroid cancer	4.92e-05	0.000999	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—thyroid cancer	4.92e-05	0.000997	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—thyroid cancer	4.88e-05	0.000991	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—thyroid cancer	4.88e-05	0.00099	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—thyroid cancer	4.84e-05	0.000983	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—thyroid cancer	4.78e-05	0.000971	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—thyroid cancer	4.72e-05	0.000959	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—thyroid cancer	4.69e-05	0.000952	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—thyroid cancer	4.69e-05	0.000951	CcSEcCtD
Vandetanib—Pain—Epirubicin—thyroid cancer	4.65e-05	0.000943	CcSEcCtD
Vandetanib—Constipation—Epirubicin—thyroid cancer	4.65e-05	0.000943	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	4.58e-05	0.00093	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—thyroid cancer	4.55e-05	0.000923	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—thyroid cancer	4.52e-05	0.000916	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—thyroid cancer	4.48e-05	0.00091	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—thyroid cancer	4.44e-05	0.000902	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—thyroid cancer	4.43e-05	0.000898	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—thyroid cancer	4.37e-05	0.000887	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	4.34e-05	0.000881	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—thyroid cancer	4.34e-05	0.00088	CcSEcCtD
Vandetanib—Pain—Doxorubicin—thyroid cancer	4.3e-05	0.000872	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—thyroid cancer	4.3e-05	0.000872	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—thyroid cancer	4.3e-05	0.000872	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—thyroid cancer	4.3e-05	0.000872	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—thyroid cancer	4.11e-05	0.000834	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—thyroid cancer	3.97e-05	0.000807	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—thyroid cancer	3.97e-05	0.000807	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—thyroid cancer	3.9e-05	0.000791	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—thyroid cancer	3.84e-05	0.00078	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—thyroid cancer	3.72e-05	0.000754	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—thyroid cancer	3.61e-05	0.000732	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—thyroid cancer	3.59e-05	0.000729	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—thyroid cancer	3.56e-05	0.000722	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—thyroid cancer	3.46e-05	0.000701	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—thyroid cancer	3.44e-05	0.000698	CcSEcCtD
Vandetanib—Rash—Epirubicin—thyroid cancer	3.43e-05	0.000695	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—thyroid cancer	3.42e-05	0.000695	CcSEcCtD
Vandetanib—Headache—Epirubicin—thyroid cancer	3.4e-05	0.000691	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—thyroid cancer	3.33e-05	0.000675	CcSEcCtD
Vandetanib—Nausea—Epirubicin—thyroid cancer	3.23e-05	0.000655	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—thyroid cancer	3.2e-05	0.000649	CcSEcCtD
Vandetanib—Rash—Doxorubicin—thyroid cancer	3.17e-05	0.000643	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—thyroid cancer	3.17e-05	0.000643	CcSEcCtD
Vandetanib—Headache—Doxorubicin—thyroid cancer	3.15e-05	0.000639	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—thyroid cancer	2.99e-05	0.000606	CcSEcCtD
Vandetanib—EGFR—Adaptive Immune System—KRAS—thyroid cancer	3.02e-06	3.46e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HRAS—thyroid cancer	3.02e-06	3.45e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—BRAF—thyroid cancer	3.01e-06	3.45e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—NRAS—thyroid cancer	2.99e-06	3.43e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—thyroid cancer	2.99e-06	3.42e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—KRAS—thyroid cancer	2.98e-06	3.41e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CCND1—thyroid cancer	2.98e-06	3.41e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HRAS—thyroid cancer	2.97e-06	3.4e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRG1—thyroid cancer	2.96e-06	3.4e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	2.93e-06	3.35e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTGS2—thyroid cancer	2.92e-06	3.34e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—SLC5A5—thyroid cancer	2.92e-06	3.34e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—KRAS—thyroid cancer	2.91e-06	3.33e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CCND1—thyroid cancer	2.9e-06	3.32e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—KRAS—thyroid cancer	2.89e-06	3.3e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PTEN—thyroid cancer	2.87e-06	3.29e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CCND1—thyroid cancer	2.87e-06	3.28e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PTEN—thyroid cancer	2.86e-06	3.28e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—HRAS—thyroid cancer	2.86e-06	3.27e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PPARG—thyroid cancer	2.85e-06	3.26e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—AKT1—thyroid cancer	2.83e-06	3.24e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—PTEN—thyroid cancer	2.8e-06	3.21e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—NRAS—thyroid cancer	2.8e-06	3.21e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—AKT1—thyroid cancer	2.8e-06	3.21e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PTEN—thyroid cancer	2.8e-06	3.2e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HRAS—thyroid cancer	2.79e-06	3.2e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PTEN—thyroid cancer	2.79e-06	3.19e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—AKT1—thyroid cancer	2.77e-06	3.18e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PTEN—thyroid cancer	2.77e-06	3.17e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TERT—thyroid cancer	2.76e-06	3.16e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—AKT1—thyroid cancer	2.76e-06	3.16e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—PTEN—thyroid cancer	2.76e-06	3.16e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.73e-06	3.13e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—AKT1—thyroid cancer	2.73e-06	3.13e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—AKT1—thyroid cancer	2.72e-06	3.11e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—AKT1—thyroid cancer	2.69e-06	3.08e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—AKT1—thyroid cancer	2.69e-06	3.08e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—AKT1—thyroid cancer	2.68e-06	3.07e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—KRAS—thyroid cancer	2.68e-06	3.07e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—thyroid cancer	2.68e-06	3.07e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HRAS—thyroid cancer	2.67e-06	3.06e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—AKT1—thyroid cancer	2.67e-06	3.06e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—BRAF—thyroid cancer	2.67e-06	3.05e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—AKT1—thyroid cancer	2.66e-06	3.05e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TERT—thyroid cancer	2.66e-06	3.05e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—thyroid cancer	2.65e-06	3.03e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PTEN—thyroid cancer	2.64e-06	3.03e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HIF1A—thyroid cancer	2.64e-06	3.03e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—BRAF—thyroid cancer	2.63e-06	3.01e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRG1—thyroid cancer	2.62e-06	3.01e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—AKT1—thyroid cancer	2.62e-06	3e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CCND1—thyroid cancer	2.61e-06	2.98e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—HRAS—thyroid cancer	2.58e-06	2.95e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—HRAS—thyroid cancer	2.58e-06	2.95e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—KRAS—thyroid cancer	2.57e-06	2.95e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HRAS—thyroid cancer	2.57e-06	2.95e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—BRAF—thyroid cancer	2.57e-06	2.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HRAS—thyroid cancer	2.56e-06	2.94e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—NRAS—thyroid cancer	2.56e-06	2.93e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—NRAS—thyroid cancer	2.55e-06	2.92e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTEN—thyroid cancer	2.55e-06	2.92e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HIF1A—thyroid cancer	2.55e-06	2.92e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—BRAF—thyroid cancer	2.53e-06	2.9e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—HRAS—thyroid cancer	2.53e-06	2.9e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—AKT1—thyroid cancer	2.52e-06	2.89e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—thyroid cancer	2.52e-06	2.89e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CCND1—thyroid cancer	2.52e-06	2.88e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PTEN—thyroid cancer	2.52e-06	2.88e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PPARG—thyroid cancer	2.51e-06	2.87e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—NRAS—thyroid cancer	2.5e-06	2.86e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—NRAS—thyroid cancer	2.5e-06	2.86e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—NRAS—thyroid cancer	2.49e-06	2.85e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HRAS—thyroid cancer	2.47e-06	2.83e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—NRAS—thyroid cancer	2.47e-06	2.83e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—AKT1—thyroid cancer	2.47e-06	2.83e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—NRAS—thyroid cancer	2.46e-06	2.82e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—HRAS—thyroid cancer	2.45e-06	2.81e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—RXRA—thyroid cancer	2.45e-06	2.81e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—thyroid cancer	2.43e-06	2.78e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PTEN—thyroid cancer	2.43e-06	2.78e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—AKT1—thyroid cancer	2.43e-06	2.78e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KRAS—thyroid cancer	2.41e-06	2.76e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.38e-06	2.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PTEN—thyroid cancer	2.38e-06	2.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—AKT1—thyroid cancer	2.36e-06	2.7e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NRAS—thyroid cancer	2.36e-06	2.7e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TERT—thyroid cancer	2.36e-06	2.7e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NRAS—thyroid cancer	2.34e-06	2.68e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTEN—thyroid cancer	2.33e-06	2.67e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—NRAS—thyroid cancer	2.33e-06	2.67e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—PTEN—thyroid cancer	2.3e-06	2.63e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HRAS—thyroid cancer	2.28e-06	2.61e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—thyroid cancer	2.28e-06	2.61e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—thyroid cancer	2.28e-06	2.61e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—thyroid cancer	2.27e-06	2.6e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—NRAS—thyroid cancer	2.27e-06	2.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—thyroid cancer	2.26e-06	2.59e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HIF1A—thyroid cancer	2.25e-06	2.58e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NRAS—thyroid cancer	2.24e-06	2.57e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—thyroid cancer	2.24e-06	2.57e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—thyroid cancer	2.23e-06	2.56e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KRAS—thyroid cancer	2.21e-06	2.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTEN—thyroid cancer	2.2e-06	2.52e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KRAS—thyroid cancer	2.2e-06	2.52e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HRAS—thyroid cancer	2.19e-06	2.51e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—BRAF—thyroid cancer	2.19e-06	2.51e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—thyroid cancer	2.18e-06	2.5e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NRAS—thyroid cancer	2.17e-06	2.48e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—thyroid cancer	2.17e-06	2.48e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—thyroid cancer	2.15e-06	2.47e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KRAS—thyroid cancer	2.15e-06	2.46e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KRAS—thyroid cancer	2.15e-06	2.46e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—thyroid cancer	2.14e-06	2.45e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KRAS—thyroid cancer	2.14e-06	2.45e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NRAS—thyroid cancer	2.13e-06	2.44e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KRAS—thyroid cancer	2.13e-06	2.43e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTEN—thyroid cancer	2.12e-06	2.43e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KRAS—thyroid cancer	2.12e-06	2.43e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—BRAF—thyroid cancer	2.11e-06	2.41e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TPR—thyroid cancer	2.1e-06	2.41e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NRAS—thyroid cancer	2.08e-06	2.39e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.07e-06	2.37e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—thyroid cancer	2.05e-06	2.35e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NRAS—thyroid cancer	2.05e-06	2.35e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—PTEN—thyroid cancer	2.03e-06	2.33e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KRAS—thyroid cancer	2.03e-06	2.32e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—thyroid cancer	2.01e-06	2.3e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—KRAS—thyroid cancer	2.01e-06	2.3e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—KRAS—thyroid cancer	2e-06	2.29e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—thyroid cancer	1.97e-06	2.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NRAS—thyroid cancer	1.96e-06	2.25e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—thyroid cancer	1.96e-06	2.24e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—thyroid cancer	1.96e-06	2.24e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTEN—thyroid cancer	1.96e-06	2.24e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—thyroid cancer	1.93e-06	2.21e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—thyroid cancer	1.93e-06	2.21e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—thyroid cancer	1.92e-06	2.2e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—thyroid cancer	1.91e-06	2.19e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NRAS—thyroid cancer	1.89e-06	2.17e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—thyroid cancer	1.89e-06	2.16e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTEN—thyroid cancer	1.88e-06	2.15e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—thyroid cancer	1.88e-06	2.15e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—thyroid cancer	1.87e-06	2.15e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—thyroid cancer	1.87e-06	2.14e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BRAF—thyroid cancer	1.87e-06	2.14e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—thyroid cancer	1.87e-06	2.14e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTEN—thyroid cancer	1.85e-06	2.12e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—thyroid cancer	1.85e-06	2.12e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—thyroid cancer	1.83e-06	2.1e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—thyroid cancer	1.83e-06	2.09e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—thyroid cancer	1.83e-06	2.09e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—thyroid cancer	1.82e-06	2.08e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—thyroid cancer	1.81e-06	2.08e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—thyroid cancer	1.81e-06	2.07e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—thyroid cancer	1.81e-06	2.07e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—thyroid cancer	1.81e-06	2.07e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—thyroid cancer	1.8e-06	2.06e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—thyroid cancer	1.79e-06	2.05e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—thyroid cancer	1.79e-06	2.05e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—thyroid cancer	1.78e-06	2.04e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—thyroid cancer	1.76e-06	2.02e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—thyroid cancer	1.72e-06	1.98e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—thyroid cancer	1.72e-06	1.97e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—thyroid cancer	1.72e-06	1.97e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—thyroid cancer	1.71e-06	1.96e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—thyroid cancer	1.7e-06	1.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—thyroid cancer	1.69e-06	1.94e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—thyroid cancer	1.67e-06	1.92e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—thyroid cancer	1.66e-06	1.9e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—thyroid cancer	1.66e-06	1.9e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—thyroid cancer	1.66e-06	1.9e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—thyroid cancer	1.65e-06	1.89e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—thyroid cancer	1.65e-06	1.89e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—thyroid cancer	1.64e-06	1.88e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—thyroid cancer	1.63e-06	1.86e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—thyroid cancer	1.62e-06	1.85e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—thyroid cancer	1.62e-06	1.85e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—thyroid cancer	1.61e-06	1.85e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—thyroid cancer	1.61e-06	1.84e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—thyroid cancer	1.6e-06	1.83e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—thyroid cancer	1.6e-06	1.83e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—thyroid cancer	1.59e-06	1.82e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—thyroid cancer	1.59e-06	1.82e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—thyroid cancer	1.59e-06	1.82e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.57e-06	1.8e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—thyroid cancer	1.56e-06	1.79e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—thyroid cancer	1.56e-06	1.78e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—thyroid cancer	1.55e-06	1.77e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—thyroid cancer	1.54e-06	1.76e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—thyroid cancer	1.54e-06	1.76e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—thyroid cancer	1.52e-06	1.75e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—thyroid cancer	1.52e-06	1.74e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—thyroid cancer	1.51e-06	1.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—thyroid cancer	1.5e-06	1.72e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—thyroid cancer	1.5e-06	1.72e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—thyroid cancer	1.49e-06	1.7e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—thyroid cancer	1.47e-06	1.68e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—thyroid cancer	1.45e-06	1.66e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—thyroid cancer	1.44e-06	1.65e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—thyroid cancer	1.44e-06	1.64e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—thyroid cancer	1.42e-06	1.63e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—thyroid cancer	1.4e-06	1.6e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—thyroid cancer	1.39e-06	1.59e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—thyroid cancer	1.38e-06	1.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—thyroid cancer	1.37e-06	1.57e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—thyroid cancer	1.37e-06	1.57e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—thyroid cancer	1.37e-06	1.57e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—thyroid cancer	1.36e-06	1.56e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—thyroid cancer	1.35e-06	1.54e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—thyroid cancer	1.33e-06	1.52e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—thyroid cancer	1.32e-06	1.52e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—thyroid cancer	1.32e-06	1.52e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—RXRA—thyroid cancer	1.32e-06	1.52e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—thyroid cancer	1.31e-06	1.51e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—thyroid cancer	1.27e-06	1.45e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—thyroid cancer	1.26e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—thyroid cancer	1.24e-06	1.42e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—thyroid cancer	1.23e-06	1.4e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—thyroid cancer	1.22e-06	1.4e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—thyroid cancer	1.22e-06	1.39e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—thyroid cancer	1.22e-06	1.39e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—thyroid cancer	1.21e-06	1.38e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—thyroid cancer	1.18e-06	1.36e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—thyroid cancer	1.18e-06	1.35e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—thyroid cancer	1.17e-06	1.34e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—thyroid cancer	1.17e-06	1.34e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—thyroid cancer	1.16e-06	1.33e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—thyroid cancer	1.14e-06	1.31e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—thyroid cancer	1.13e-06	1.29e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—thyroid cancer	1.08e-06	1.24e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—thyroid cancer	1.07e-06	1.22e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—thyroid cancer	1.06e-06	1.22e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—thyroid cancer	1.05e-06	1.2e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—thyroid cancer	1.04e-06	1.2e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—thyroid cancer	1.03e-06	1.18e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—thyroid cancer	1.01e-06	1.16e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—thyroid cancer	1.01e-06	1.16e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—thyroid cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—thyroid cancer	9.92e-07	1.14e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—thyroid cancer	9.69e-07	1.11e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—thyroid cancer	8.97e-07	1.03e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—thyroid cancer	8.88e-07	1.02e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—thyroid cancer	8.58e-07	9.83e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—thyroid cancer	8.56e-07	9.8e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—thyroid cancer	8.35e-07	9.57e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—thyroid cancer	7.58e-07	8.68e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—thyroid cancer	6.57e-07	7.53e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—thyroid cancer	6.12e-07	7.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—thyroid cancer	5.73e-07	6.56e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—thyroid cancer	3.3e-07	3.78e-06	CbGpPWpGaD
